Crossmark

PD-L1 subpopulations of metastatic urothelial carcinoma demonstrate heterogeneity to chemotherapy: an integrated analysis of digitized trial results

Published Online: 2026-01-30

Authors

Zhou, Jie

Jiang, Xun

Liu, Qing

Xia, H. Amy

Wei, Peng

Hobbs, Brian P.
License Information

Text and Data Mining valid from 2026-01-30

Version of Record valid from 2026-01-30
More Information

Article History

Received: 6 June 2025

Accepted: 15 January 2026

First Online: 30 January 2026

Declarations

:

: B.P.H. has served on scientific advisory committees for Amgen, Bayer HealthCare Pharmaceuticals Inc., CSL Behring, Sana Biotechnology, and Miltenyi.

Document is current